{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:51:43Z","timestamp":1782028303556,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151153"],"award-info":[{"award-number":["OPP1151153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1116967"],"award-info":[{"award-number":["OPP1116967"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,7]]},"DOI":"10.1093\/cid\/ciy1076","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T23:18:01Z","timestamp":1544656681000},"page":"S154-S160","source":"Crossref","is-referenced-by-count":8,"title":["Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries"],"prefix":"10.1093","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3027-2838","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Debellut","sequence":"first","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Hendrix","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia E","family":"Pitzer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Neuzil","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagna","family":"Constenla","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naor","family":"Bar-Zeev","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Marfin","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Pecenka","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"key\n\t\t\t\t2019030806460570600_CIT0001","first-page":"153","article-title":"Typhoid vaccines: WHO position paper","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)00530-7","article-title":"Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial","volume":"16","author":"Arjyal","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0003","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3201\/eid1605.091917","article-title":"Fluoroquinolone-resistant typhoid, South Africa","volume":"16","author":"Keddy","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0004","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/mBio.00105-18","article-title":"Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins","volume":"9","author":"Klemm","year":"2018","journal-title":"mBio"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3201\/eid2004.131536","article-title":"Salmonella subtypes with increased MICs for azithromycin in travelers returned to The Netherlands","volume":"20","author":"Hassing","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0006","first-page":"CD001261","article-title":"Vaccines for preventing typhoid fever","volume":"5","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0007","volume-title":"Background paper to SAGE on typhoid vaccine policy recommendations","year":"2017"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0009"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0010","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1016\/j.vaccine.2016.05.027","article-title":"The impact of implementing a demand forecasting system into a low-income country\u2019s supply chain","volume":"34","author":"Mueller","year":"2016","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0011"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0012","volume-title":"World population prospects: the 2017 revision","year":"2017"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0013","doi-asserted-by":"crossref","first-page":"e0199470","DOI":"10.1371\/journal.pone.0199470","article-title":"Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries","volume":"13","author":"Debellut","year":"2018","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0014","doi-asserted-by":"crossref","first-page":"e0005376","DOI":"10.1371\/journal.pntd.0005376","article-title":"The burden of typhoid fever in low- and middle-income countries: a meta-regression approach","volume":"11","author":"Antill\u00f3n","year":"2017","journal-title":"Plos Negl Trop Dis"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0015","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0016","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/S2214-109X(17)30328-5","article-title":"Updated estimates of typhoid fever burden in sub-Saharan Africa","volume":"5","author":"Kim","year":"2017","journal-title":"Lancet Glob Health"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0017","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Vos","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0018","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Crump","year":"2004","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0019","unstructured":"Johns Hopkins Bloomberg School of Public Health. International vaccine access center: resources. Available at: http:\/\/ivac.jhu.edu\/. Accessed 28 July 2017."},{"key":"key\n\t\t\t\t2019030806460570600_CIT0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4161\/hv.6.9.12587","article-title":"Forecasting dengue vaccine demand in disease endemic and non-endemic countries","volume":"6","author":"Amarasinghe","year":"2014","journal-title":"Human Vaccines"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0021","unstructured":"World Health Organization. Estimates of MCV1 coverage. Available at: http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/timeseries\/tswucoveragemcv1.html. Accessed 26 June 2018."},{"key":"key\n\t\t\t\t2019030806460570600_CIT0022","unstructured":"Bharat Biotech. Typbar TCV\u00ae from Bharat Biotech, World\u2019s first typhoid conjugate vaccine prequalified by WHO. 2018. Available at: http:\/\/www.who.int\/medicines\/news\/2017\/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf. Accessed 7 August 2018."},{"key":"key\n\t\t\t\t2019030806460570600_CIT0023","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1080\/21645515.2017.1333681","article-title":"A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions","volume":"13","author":"Mogasale","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0024","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12879-016-2074-1","article-title":"Geographical distribution of typhoid risk factors in low and middle income countries","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2458-7-289","article-title":"Comparisons of predictors for typhoid and paratyphoid fever in Kolkata, India","volume":"7","author":"Sur","year":"2007","journal-title":"BMC Public Health"},{"key":"key\n\t\t\t\t2019030806460570600_CIT0026","doi-asserted-by":"crossref","first-page":"110008","DOI":"10.1098\/rsob.110008","article-title":"Combined high-resolution genotyping and geospatial analysis reveals modes of endemic urban typhoid fever transmission","volume":"1","author":"Baker","year":"2011","journal-title":"Open Biol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/Supplement_2\/S154\/28023900\/ciy1076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T06:54:31Z","timestamp":1552028071000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/Supplement_2\/S154\/5371221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":26,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2019,3,7]]},"published-print":{"date-parts":[[2019,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy1076","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,15]]},"published":{"date-parts":[[2019,3,7]]}}}